Condition: Immunological Non-Responders in People With HIV · Sponsor: Beijing 302 Hospital
This study focuses on people with HIV who experience incomplete immune reconstitution despite suppressive antiretroviral therapy (ART), characterized by persistently low CD4⁺ T cell counts and residual inflammation. The underlying cause is largely attributed to the persistent HIV latent reservoir. Recent evidence indicates that rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) commonly used in ART, has an immunomodulatory function beyond its antiviral activity. It activates the CARD8 inflammasome - an intracellular "kill switch" - triggering pyroptosis selectively in HIV-infected cells. In this study, rilpivirine will be added to suppressive ART in patients with incomplete immune reconstitution. The investigators hypothesize that this strategy will reduce the latent reservoir, restore CD4⁺ T cell counts and function, attenuate excessive immune activation, and ultimately improve long-term clinical outcomes.
This description comes directly from the study's public registry record.
Ruonan Xu, MD · +8618611314169 · xuruonan2004@aliyun.com
Always discuss trial participation with your own doctor first.
| The Fifth Medical Center of PLA General Hospital | Beijing, Beijing Municipality, China | Recruiting |
| 302 Hospital | Beijing, China | Recruiting |
| Guangzhou Eighth People's Hospital | Guangzhou, China | Recruiting |
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou, China | Recruiting |
| Shenzhen Third People's Hospital | Shenzhen, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07637877